Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Condition: Leukemia; Lymphoma
MeSH terms: Lymphoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem
      cell transplant helps stop the growth of cancer cells. It also helps stop the patient's
      immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as
      rituximab, can find cancer cells and either kill them or deliver cancer-killing substances to
      them without harming normal cells. The donated stem cells may replace the patient's immune
      cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the
      transplanted cells from a donor can also make an immune response against the body's normal
      cells. Giving rituximab before transplant and cyclosporine and mycophenolate mofetil after
      transplant may stop this from happening.

      PURPOSE: This phase II trial is studying the side effects and how well giving chemotherapy
      and radiation therapy together with rituximab and donor stem cell transplant works in
      treating patients with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
    


Intervention name(s): anti-thymocyte globulin; filgrastim; graft-versus-tumor induction therapy; rituximab; cyclophosphamide; cyclosporine; fludarabine phosphate; mycophenolate mofetil; nonmyeloablative allogeneic hematopoietic stem cell transplantation; total-body irradiation
Intervention type(s): Biological; Biological; Biological; Biological; Drug; Drug; Drug; Drug; Procedure; Radiation
Intervention MeSH terms: Cyclosporine; Mycophenolic Acid; Cyclophosphamide; Rituximab; Fludarabine; Fludarabine phosphate; Cyclosporins; Antilymphocyte Serum
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: noncontiguous stage II adult diffuse large cell lymphoma; recurrent adult diffuse large cell lymphoma; stage III adult diffuse large cell lymphoma; stage IV adult diffuse large cell lymphoma; B-cell chronic lymphocytic leukemia; refractory chronic lymphocytic leukemia; stage III chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; noncontiguous stage II mantle cell lymphoma; recurrent mantle cell lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma; noncontiguous stage II grade 1 follicular lymphoma; noncontiguous stage II grade 2 follicular lymphoma; recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; stage III grade 1 follicular lymphoma; stage III grade 2 follicular lymphoma; stage IV grade 1 follicular lymphoma; stage IV grade 2 follicular lymphoma; noncontiguous stage II small lymphocytic lymphoma; recurrent small lymphocytic lymphoma; stage III small lymphocytic lymphoma; stage IV small lymphocytic lymphoma; noncontiguous stage II marginal zone lymphoma; recurrent marginal zone lymphoma; splenic marginal zone lymphoma; stage III marginal zone lymphoma; stage IV marginal zone lymphoma; noncontiguous stage II adult immunoblastic large cell lymphoma; stage III adult immunoblastic large cell lymphoma; stage IV adult immunoblastic large cell lymphoma; extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue; nodal marginal zone B-cell lymphoma; recurrent adult immunoblastic large cell lymphoma